Dswiss Inc
DSwiss Inc operates with a capital structure that shows a negative equity position of -$9,350,000, indicating a significant debt burden relative to its equity base. The company's liquidity position is further strained by a current ratio of 0.71, suggesting that it may struggle to meet short-term obligations without external financing [doc:DSWISS-FINANCIALS-2024]. The debt-to-equity ratio of -13.55 highlights the company's reliance on debt financing, which is exacerbated by a negative net income of -$76,860,000 and an operating loss of -$60,880,000 [doc:DSWISS-FINANCIALS-2024]. Profitability metrics for DSwiss Inc are weak compared to industry benchmarks. The company's return on assets (ROA) is -0.1135, indicating that it is not generating a return on its asset base, while its return on equity (ROE) of 8.2203 is also below the industry median. Gross profit of $564,570,000 is insufficient to cover operating expenses, leading to a negative operating income [doc:DSWISS-FINANCIALS-2024]. The company's revenue is concentrated in two segments: investment holding and health care products and services. Geographically, DSwiss Inc is heavily exposed to the ASEAN region, particularly Malaysia, where it operates and sells its products. This concentration increases vulnerability to regional economic and regulatory shifts [doc:DSWISS-10K-2023]. DSwiss Inc's growth trajectory is uncertain, with no clear revenue growth indicated in the latest financials. The company's operating cash flow is negative at -$94,300,000, and its free cash flow is -$53,050,000, suggesting that it is not generating sufficient cash to sustain operations or fund expansion. Capital expenditures of -$41,030,000 further indicate a lack of investment in growth initiatives [doc:DSWISS-FINANCIALS-2024]. Risk factors for DSwiss Inc include liquidity constraints and a high debt burden, which could lead to financial distress. The company's dilution potential is currently low, but its negative equity position and reliance on debt financing could increase the likelihood of future dilution. Adjustments in the valuation model reflect the company's weak financial position and limited ability to service debt [doc:DSWISS-FINANCIALS-2024]. Recent events, including the 10-K filing for 2023, highlight the company's financial challenges and operational focus on private label manufacturing. The filing also notes the company's exposure to regulatory and market risks in the ASEAN region [doc:DSWISS-10K-2023].
Business. DSwiss Inc is a biotech nutraceutical company that offers healthcare, skincare, personal care, and pet care products, primarily in Malaysia and the ASEAN region, generating revenue through private label manufacturing and end-to-end services for nutraceutical and skincare OEM/ODM products [doc:DSWISS-10K-2023].
Classification. DSwiss Inc is classified under the Consumer Cyclicals economic sector, Retailers business sector, and Miscellaneous Specialty Retailers industry, with a confidence level of 0.92 [doc:-CLASSIFICATION-2024].
- DSwiss Inc has a negative equity position and a high debt-to-equity ratio, indicating significant financial leverage and potential insolvency risk.
- The company's profitability metrics are below industry medians, with a negative return on assets and insufficient gross profit to cover operating expenses.
- Revenue is concentrated in two segments and the ASEAN region, increasing exposure to regional economic and regulatory risks.
- DSwiss Inc is not generating positive operating or free cash flow, limiting its ability to fund operations or growth.
- The company's liquidity position is weak, with a current ratio below 1 and negative net cash after debt.
- Recent filings highlight financial challenges and operational focus on private label manufacturing in the ASEAN region.
- --
- ## RATIONALES
- Net cash is negative after subtracting total debt.